The contribution of targeted therapy to the neoadjuvant chemoradiation of rectal cancer

Francesco Torino, Roberta Sarmiento, Giampietro Gasparini

Research output: Contribution to journalArticlepeer-review

Abstract

Neoadjuvant chemoradiation therapy is a commonly used option aimed to make less aggressive surgery approaches and to improve quality of life allowing a high proportion of patients operated with sphincter-sparing surgical techniques in locally advanced rectal cancer (LARC). During the last 5 years a number of studies have tested the efficacy of more intensive chemotherapeutic approaches by combining irinotecan or oxaliplatin with fluoropyrimidines and standard radiation treatments as well as testing combined treatments with targeted agents directed against epidermal growth factor receptor (EGFR) or angiogenesis. Herein, we review the results and critiques of the published studies based on the introduction of novel targeted agents in neoadjuvant therapy of LARC.

Original languageEnglish
Pages (from-to)283-305
Number of pages23
JournalCritical Reviews in Oncology/Hematology
Volume87
Issue number3
DOIs
Publication statusPublished - Sep 2013

Keywords

  • Bevacizumab
  • Cetuximab
  • Neoadjuvant-treatment
  • Rectal cancer
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Fingerprint Dive into the research topics of 'The contribution of targeted therapy to the neoadjuvant chemoradiation of rectal cancer'. Together they form a unique fingerprint.

Cite this